Zydus gets USFDA nod to market cancer treatment generic injection
The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.
Zydus Lifesciences on Thursday said it has received approval from the US health regulator to market a cancer treatment generic injection in the American market. The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.
The drug will be manufactured at the group's injectable manufacturing facility at Ahmedabad, it added.
As per IQVIA MAT May 2023 data, Plerixafor injection single-dose vials had annual sales of USD 210 million in the US.
Shares of Zydus were trading 4.39 per cent up at Rs 649.80 apiece on the BSE.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.